Biological and chemical approaches to diseases of proteostasis deficiency

Annual Review of Biochemistry

Volumn 78, Issue , 2009, Pages 959-991

  Powers, Evan T ^a   Morimoto, Richard I ^b   Dillin, Andrew ^c   Kelly, Jeffery W ^a   Balch, William E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Aging; Amyloid; Chaperones; Heat shock response; Protein folding and misfolding; Unfolded protein response

Indexed keywords

SPHINGOSINE 1 PHOSPHATE RECEPTOR;

HEART DEATH; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN DISEASES; CYSTIC FIBROSIS; HUMANS; MOLECULAR CHAPERONES; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STABILITY; PROTEINS;

EID: 67650410543     PISSN: 00664154     EISSN: 00664154     Source Type: Book Series    
DOI: 10.1146/annurev.biochem.052308.114844     Document Type: Review

References (171)

1. Balch WE, Morimoto RI, Dillin A, Kelly JW. 2008. Adapting proteostasis for disease intervention. Science 319:916-19
2. Braun P, Rietman E, Vidal M. 2008. Networking metabolites and diseases. Proc. Natl. Acad. Sci. USA 105:9849-50
3. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. 2007. The human disease network. Proc. Natl. Acad. Sci. USA 104:8685-90
4. Ideker T, Sharan R. 2008. Protein networks in disease. Genome Res. 18:644-52
5. Anfinsen CB. 1973. Principles that govern the folding of protein chains. Science 181:223-30
6. Oliveberg M,Wolynes PG. 2005. The experimental survey of protein-folding energy landscapes. Q. Rev. Biophys. 38:245-88
7. Udgaonkar JB. 2008. Multiple routes and structural heterogeneity in protein folding. Annu. Rev. Biophys. 37:489-510
8. Dill KA, Ozkan SB, Shell MS, Weikl TR. 2008. The protein folding problem. Annu. Rev. Biophys. 37:289-316
9. Auer S, Miller MA, Krivov SV, Dobson CM, Karplus M,Vendruscolo M. 2007. Importance of metastable states in the free energy landscapes of polypeptide chains. Phys. Rev. Lett. 99:178104
10. Luheshi LM, Crowther DC, Dobson CM. 2008. Protein misfolding and disease: from the test tube to the organism. Curr. Opin. Chem. Biol. 12:25-31
11. Uversky VN, Oldfield CJ, Dunker AK. 2008. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu. Rev. Biophys. 37:215-46
12. Das R, Baker D. 2008. Macromolecular modeling with rosetta. Annu. Rev. Biochem. 77:363-82
13. Powers ET, Balch WE. 2008. Costly mistakes: translational infidelity and protein homeostasis. Cell 134:204-6
14. Drummond DA,Wilke CO. 2008. Mistranslation-induced protein misfolding as a dominant constraint on coding-sequence evolution. Cell 134:341-52
15. Zhou HX, Rivas G, Minton AP. 2008. Macromolecular crowding and confinement: biochemical, biophysical, and potential physiological consequences. Annu. Rev. Biophys. 37:375-97
16. Kelly JW, Balch WE. 2006. The integration of cell and chemical biology in protein folding. Nat. Chem. Biol. 2:224-27
17. Morimoto RI. 2008. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 22:1427-38
18. Young JC, Agashe VR, Siegers K, Hartl FU. 2004. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol. 5:781-91
19. Saibil HR. 2008. Chaperone machines in action. Curr. Opin. Struct. Biol. 18:35-42
20. Bukau B,Weissman J, Horwich A. 2006. Molecular chaperones and protein quality control. Cell 125:443-51
21. Brodsky JL, Chiosis G. 2006. Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Curr. Top. Med. Chem. 6:1215-25
22. Ni M, Lee AS. 2007. ER chaperones in mammalian development and human diseases. FEBS Lett. 581:3641-51
23. Shimizu Y, Hendershot LM. 2007. Organization of the functions and components of the endoplasmic reticulum. Adv. Exp. Med. Biol. 594:37-46
24. Appenzeller-Herzog C, Ellgaard L. 2008. The human PDI family: versatility packed into a single fold. Biochim. Biophys. Acta 1783:535-48
25. Nagata K. 2003. HSP47 as a collagen-specific molecular chaperone: function and expression in normal mouse development. Semin. Cell Dev. Biol. 14:275-82
26. Hussain MM, Rava P, Pan X, Dai K, Dougan SK, et al. 2008. Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism. Curr. Opin. Lipidol. 19:277-84
27. Horwich AL, Fenton WA, Chapman E, Farr GW. 2007. Two families of chaperonin: physiology and mechanism. Annu. Rev. Cell Dev. Biol. 23:115-45
28. Tang YC, Chang HC, Chakraborty K, Hartl FU, Hayer-Hartl M. 2008. Essential role of the chaperonin folding compartment in vivo. EMBO J. 27:1458-68
29. Sharma S, Chakraborty K, Muller BK, Astola N, Tang YC, et al. 2008. Monitoring protein conformation along the pathway of chaperonin-assisted folding. Cell 133:142-53
30. Konstantinova IM, Tsimokha AS, Mittenberg AG. 2008. Role of proteasomes in cellular regulation. Int. Rev. Cell Mol. Biol. 267:59-124
31. Tasaki T, Kwon YT. 2007. The mammalian N-end rule pathway: new insights into its components and physiological roles. Trends Biochem. Sci. 32:520-28
32. Levine B, Kroemer G. 2008. Autophagy in the pathogenesis of disease. Cell 132:27-42
33. Kundu M, Thompson CB. 2008. Autophagy: basic principles and relevance to disease. Annu. Rev. Pathol. 3:427-55
34. Malhotra JD, Kaufman RJ. 2007. The endoplasmic reticulum and the unfolded protein response. Semin. Cell Dev. Biol. 18:716-31
35. Ron D, Walter P. 2007. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8:519-29
36. Lin JH,Walter P, Yen TS. 2008. Endoplasmic reticulum stress in disease pathogenesis. Annu. Rev. Pathol. 3:399-425
37. Shamovsky I, Nudler E. 2008. New insights into the mechanism of heat shock response activation. Cell Mol. Life Sci. 65:855-61
38. PetersenOH,Michalak M,Verkhratsky A. 2005. Calcium signalling: past, present and future. Cell Calcium 38:161-69
39. Burdakov D, Petersen OH, Verkhratsky A. 2005. Intraluminal calcium as a primary regulator of endoplasmic reticulum function. Cell Calcium 38:303-10
40. Medzhitov R. 2008. Origin and physiological roles of inflammation. Nature 454:428-35
41. Zhang K, Kaufman RJ. 2008. From endoplasmic-reticulum stress to the inflammatory response. Nature 454:455-62
42. Prahlad V, Cornelius T, Morimoto RI. 2008. Regulation of the cellular heat shock response in Caenorhabditis elegans by thermosensory neurons. Science 320:811-14
43. Murphy KG, Bloom SR. 2006. Gut hormones and the regulation of energy homeostasis. Nature 444:854-59
44. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, et al. 2004. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. USA 101:6062-67
45. Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, et al. 2005. The biological and chemical basis for tissue-selective amyloid disease. Cell 121:73-85
46. Wiseman RL, Powers ET, Buxbaum JN, Kelly JW, Balch WE. 2007. An adaptable standard for protein export from the endoplasmic reticulum. Cell 131:809-21
47. Haynes C, Oldfield CJ, Ji F, Klitgord N, Cusick ME, et al. 2006. Intrinsic disorder is a common feature of hub proteins from four eukaryotic interactomes. PLoS Comput. Biol. 2:e100
48. Hillenmeyer ME, Fung E,Wildenhain J, Pierce SE, Hoon S, et al. 2008. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320:362-65
49. Brignull HR, Morley JF, Morimoto RI. 2007. The stress of misfolded proteins: C. elegans models for neurodegenerative disease and aging. Adv. Exp. Med. Biol. 594:167-89
50. Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI. 2006. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311:1471-74
51. Palotai R, Szalay MS, Csermely P. 2008. Chaperones as integrators of cellular networks: changes of cellular integrity in stress and diseases. IUBMB Life 60:10-18
52. Conn PM, Ulloa-Aguirre A, Ito J, Janovick JA. 2007. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacol. Rev. 59:225-50
53. Millar NS, Harkness PC. 2008. Assembly and trafficking of nicotinic acetylcholine receptors (Review). Mol. Membr. Biol. 25:279-92
54. Grabowski GA. 2008. Treatment perspectives for the lysosomal storage diseases. Expert Opin. Emerg. Drugs 13:197-211
55. Sawkar AR, Cheng W-C, Beutler E, Wong C-H, Balch WE, Kelly JW. 2002. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. USA 99:15428-33
56. Fan J-Q, Ishii S, Asano N, Suzuki Y. 1999. Accelerated transport and maturation of lysosomal alphagalactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat. Med. 5:112-15
57. Yoo CL, Yu GJ, Yang B, Robins LI, Verkman AS, Kurth MJ. 2008. 4′-Methyl-4,5′-bithiazole-based correctors of defective △F508-CFTR cellular processing. Bioorg. Med. Chem. Lett. 18:2610-14
58. Amaral MD, Kunzelmann K. 2007. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol. Sci. 28:334-41
59. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, et al. 2005. Small-molecule correctors of defective △F508-CFTR cellular processing identified by high-throughput screening. J. Clin. Investig. 115:2564-71
60. Loo TW, Bartlett MC, Clarke DM. 2008. Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem. J. 413:29-36
61. Noel S, Strale PO, Dannhoffer L,Wilke M, DeJonge H, et al. 2008. Stimulation of salivary secretion in vivo by CFTR potentiators in Cftr+/+ and Cftr-/- mice. J. Cyst. Fibros. 7:128-33
62. Wang Y, Bartlett MC, Loo TW, Clarke DM. 2006. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol. Pharmacol. 70:297-302
63. Wang Y, Loo TW, Bartlett MC, Clarke DM. 2007. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem. J. 406:257-63
64. Yu Z, Sawkar AR, Kelly JW. 2007. Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J. 274:4944-50
65. Yu Z, Sawkar AR, Whalen LJ, Wong CH, Kelly JW. 2007. Isofagomine- and 2,5-anhydro-2,5-iminod-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J. Med. Chem. 50:94-100
66. Hammarstrom P,Wiseman RL, Powers ET, Kelly JW. 2003. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299:713-16
67. Johnson SM,Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. 2005. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38:911-21
68. Mu T-W, Fowler DM, Kelly JW. 2008. Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol. 6:e26
69. Obrenovitch TP. 2008. Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol. Rev. 88:211-47
70. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, et al. 2005. A selective inhibitor of eIF2α dephosphorylation protects cells from ER stress. Science 307:935-39
71. Boyce M, Py BF, Ryazanov AG, Minden JS, Long K, et al. 2008. A pharmacoproteomic approach implicates eukaryotic elongation factor 2 kinase in ER stress-induced cell death. Cell Death Differ. 15:589-99
72. Trott A, West JD, Klaic L, Westerheide SD, Silverman RB, et al. 2008. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol. Biol. Cell 19:1104-12
73. Corson TW, Crews CM. 2007. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130:769-74
74. Westerheide SD, Morimoto RI. 2005. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J. Biol. Chem. 280:33097-100
75. Wang J, Gines S, MacDonald ME, Gusella JF. 2005. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci. 6:1
76. Zhang T, Hamza A, Cao X,Wang B, Yu S, et al. 2008. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7:162-70
77. Jung HW, Chung YS, Kim YS, Park YK. 2007. Celastrol inhibits production of nitric oxide and proin-flammatory cytokines throughMAPKsignal transduction and NF-κB in LPS-stimulatedBV-2 microglial cells. Exp. Mol. Med. 39:715-21
78. Yang H, Shi G, Dou QP. 2007. The tumor proteasome is a primary target for the natural anticancer compoundWithaferin A isolated from "Indian winter cherry". Mol. Pharmacol. 71:426-37
79. Li H, Zhang YY, Tan HW, Jia YF, Li D. 2008. Therapeutic effect of tripterine on adjuvant arthritis in rats. J. Ethnopharmacol. 118:479-84
80. Merrill GF, Goldberg E. 2001. Antioxidant properties of acetaminophen and cardioprotection. Basic Res. Cardiol. 96:423-30
81. Shertzer HG, Schneider SN, Kendig EL, Clegg DJ, D'Alessio DA, Genter MB. 2008. Acetaminophen normalizes glucose homeostasis in mouse models for diabetes. Biochem. Pharmacol. 75:1402-10
82. Gorlach A, Klappa P, Kietzmann T. 2006. The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid. Redox Signal. 8:1391-418
83. Mu T-W, Ong DST, Wang Y-J, Balch WE, Yates JR, et al. 2008. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134:769-81
84. Lee KK,Workman JL. 2007. Histone acetyltransferase complexes: One size doesn't fit all. Nat. Rev.Mol. Cell Biol. 8:284-95
85. Sadoul K, Boyault C, Pabion M, Khochbin S. 2008. Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie 90:306-12
86. Echaniz-Laguna A, Bousiges O, Loeffler JP, Boutillier AL. 2008. Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases. Curr. Med. Chem. 15:1263-73
87. Xu WS, Parmigiani RB, Marks PA. 2007. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541-52
88. Martin M, Kettmann R, Dequiedt F. 2007. Class IIa histone deacetylases: regulating the regulators. Oncogene 26:5450-67
89. Guarente L. 2007. Sirtuins in aging and disease. Cold Spring Harb. Symp. Quant. Biol. 72:483-88
90. Feige JN, Johan A. 2008.Transcriptional targets of sirtuins in the coordination of mammalian physiology. Curr. Opin. Cell Biol. 20:303-9
91. Chen D, Guarente L. 2007. SIR2: a potential target for calorie restriction mimetics. Trends Mol. Med. 13:64-71
92. Fraga MF, Esteller M. 2007. Epigenetics and aging: the targets and the marks. Trends Genet. 23:413-18
93. Westphal CH, Dipp MA, Guarente L. 2007. A therapeutic role for sirtuins in diseases of aging? Trends Biochem. Sci. 32:555-60
94. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712-16
95. Milne JC, Denu JM. 2008. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol. 12:11-17
96. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F. 2008. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 18:291-97
97. Matthias P, Yoshida M, Khochbin S. 2008. HDAC6 a new cellular stress surveillance factor. Cell Cycle 7:7-10
98. Westerheide SD, Anckar J, Stevens SM, Sistonen L, Morimoto RI. 2009. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323:1063-66
99. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, et al. 2006. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313:1137-40
100. Singh OV, Pollard HB, Zeitlin PL. 2008. Chemical rescue of △F508-CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells. Mol. Cell Proteomics 7:1099-110
101. Pruliere-Escabasse V, Planes C, Escudier E, Fanen P, Coste A, Clerici C. 2007. Modulation of epithelial sodium channel trafficking and function by sodium 4-phenylbutyrate in human nasal epithelial cells. J. Biol. Chem. 282:34048-57
102. Perlmutter DH. 2006. The role of autophagy in α-1-antitrypsin deficiency: a specific cellular response in genetic diseases associated with aggregation-prone proteins. Autophagy 2:258-63
103. Ding WX, Yin XM. 2008. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 4:141-50
104. Dice JF. 2007. Chaperone-mediated autophagy. Autophagy 3:295-99
105. Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P. 2008. Regulation of macroautophagy bymTOR and Beclin 1 complexes. Biochimie 90:313-23
106. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. 2009. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine- expanded huntingtin and related proteinopathies. Cell Death Differ. 16:46-56
107. Zemke D, Azhar S, Majid A. 2007. The mTOR pathway as a potential target for the development of therapies against neurological disease. Drug News Perspect. 20:495-99
108. Reiling JH, Sabatini DM. 2008. Increased mTORC1 signaling UPRegulates stress. Mol. Cell 29:533-35
109. Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, et al. 2008. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 29:541-51
110. Perlmutter DH. 2009. Autophagic disposal of the aggregation-prone protein that causes liver inflammation and carcinogenesis in α-1-antitrypsin deficiency. Cell Death Differ. 16:39-45
111. Granell S, Baldini G. 2008. Inclusion bodies and autophagosomes: Are ER-derived protective organelles different than classical autophagosomes? Autophagy 4:375-77
112. Hetz C, Glimcher L. 2008. The daily job of night killers: alternative roles of the BCL-2 family in organelle physiology. Trends Cell Biol. 18:38-44
113. Garcia SM, Casanueva MO, Silva MC, Amaral MD,Morimoto RI. 2007. Neuronal signaling modulates protein homeostasis in Caenorhabditis elegans postsynaptic muscle cells. Genes Dev. 21:3006-16
114. Giannakou ME, Partridge L. 2007. Role of insulin-like signalling in Drosophila lifespan. Trends Biochem. Sci. 32:180-88
115. Mair W, Dillin A. 2008. Aging and survival: the genetics of life span extension by dietary restriction. Annu. Rev. Biochem. 77:727-54
116. Hansen M, Hsu AL, Dillin A, Kenyon C. 2005. New genes tied to endocrine, metabolic, and dietary regulation of lifespan from a Caenorhabditis elegans genomic RNAi screen. PLoS Genet. 1:119-28
117. Tullet JM, Hertweck M, An JH, Baker J, Hwang JY, et al. 2008. Direct inhibition of the longevitypromoting factor SKN-1 by insulin-like signaling in C. elegans. Cell 132:1025-38
118. Budovskaya YV, Wu K, Southworth LK, Jiang M, Tedesco P, et al. 2008. An elt-3/elt-5/elt-6 GATA transcription circuit guides aging in C. elegans. Cell 134:291-303
119. Kahn SE, Hull RL, Utzschneider KM. 2006. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-46
120. Gregor MG, Hotamisligil GS. 2007. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J. Lipid Res. 48:1905-14
121. Scheuner D, Kaufman RJ. 2008. The unfolded protein response: a pathway that links insulin demand with β-cell failure and diabetes. Endocr. Rev. 29:317-33
122. Gregor MF, Hotamisligil GS. 2007. Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J. Lipid Res. 48:1905-14
123. Eizirik DL, Cardozo AK, Cnop M. 2008. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev. 29:42-61
124. Haataja L, Gurlo T, Huang CJ, Butler PC. 2008. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 29:303-16
125. Hull RL,Westermark GT,Westermark P, Kahn SE. 2004. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 89:3629-43
126. Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ. 2008. CHOP deletion reduces oxidative stress, improves β-cell function, and promotes cell survival in multiple mouse models of diabetes. J. Clin. Investig. 118:3378-89
127. Dashwood RH, Ho E. 2007. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin. Cancer Biol. 17:363-69
128. Metoyer CF, Pruitt K. 2008. The role of sirtuin proteins in obesity. Pathophysiology 15:103-8
129. Elliott PJ, Jirousek M. 2008. Sirtuins: novel targets for metabolic disease. Curr. Opin. Investig. Drugs 9:371-78
130. Bordone L, Guarente L. 2007. Sirtuins and β-cell function. Diabetes Obes. Metab. 9(Suppl. 2):23-27
131. Salehi M, Aulinger BA, D'Alessio DA. 2008. Targeting β-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr. Rev. 29:367-79
132. Halimi S. 2008. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? Diabetes Metab. 34(Suppl. 2):S91-95
133. Imai J, Katagiri H, Yamada T, Ishigaki Y, Suzuki T, et al. 2008. Regulation of pancreatic β-cell mass by neuronal signals from the liver. Science 322:1250-54
134. Neckers L. 2007. Heat shock protein 90: the cancer chaperone. J. Biosci. 32:517-30
135. Brown MA, Zhu L, Schmidt C, Tucker PW. 2007. Hsp90-from signal transduction to cell transformation. Biochem. Biophys. Res. Commun. 363:241-46
136. Pearl LH, Prodromou C, Workman P. 2008. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 410:439-53
137. Chiosis G. 2006. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 6:1183-91
138. Solit DB, Chiosis G. 2008. Development and application of Hsp90 inhibitors. Drug Discov. Today 13:38-43
139. Taldone T, Gozman A, Maharaj R, Chiosis G. 2008. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 8:370-74
140. Powers MV,Workman P. 2007. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 581:3758-69
141. Wang L, Zhou GB, Liu P, Song JH, Liang Y, et al. 2008. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 105:4826-31
142. Dilda PJ, Hogg PJ. 2007. Arsenical-based cancer drugs. Cancer Treat. Rev. 33:542-64
143. Nakamura T, Lipton SA. 2008. Emerging roles of S-nitrosylation in protein misfolding and neurodegenerative diseases. Antioxid. Redox Signal. 10:87-101
144. Yang H, Landis-Piwowar KR, Chen D, Milacic V, Dou QP. 2008. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Curr. Protein Pept. Sci. 9:227-39
145. Bossi G, Sacchi A. 2007. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 29:272-84
146. Chauhan D, Hideshima T, Anderson KC. 2008. Targeting proteasomes as therapy in multiple myeloma. Adv. Exp. Med. Biol. 615:251-60
147. Mateos MV, San Miguel JF. 2007. Bortezomib in multiple myeloma. Best Pract. Res. Clin. Haematol. 20:701-15
148. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. 2006. Opposing activities protect against age-onset proteotoxicity. Science 313:1604-10
149. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8:101-12
150. Kaganovich D, Kopito R, Frydman J. 2008. Misfolded proteins partition between two distinct quality control compartments. Nature 454:1088-95
151. Morimoto RI. 2006. Stress, aging, and neurodegenerative disease. N. Engl. J. Med. 355:2254-55
152. Brignull HR, Moore FE, Tang SJ, Morimoto RI. 2006. Polyglutamine proteins at the pathogenic threshold display neuron-specific aggregation in a pan-neuronal Caenorhabditis elegans model. J. Neurosci. 26:7597-606
153. Shao J, Diamond MI. 2007. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 16(Spec. 2):R115-23
154. Wang H, Duennwald ML, Roberts BE, Rozeboom LM, Zhang YL, et al. 2008. Direct and selective elimination of specific prions and amyloids by 4,5-dianilinophthalimide and analogs. Proc. Natl. Acad. Sci. USA 105:7159-64
155. Levy M, Porat Y, Bacharach E, Shalev DE, Gazit E. 2008. Phenolsulfonphthalein, but not phenolphthalein, inhibits amyloid fibril formation: implications for the modulation of amyloid self-assembly. Biochemistry 47:5896-904
156. Gan L. 2007. Therapeutic potential of sirtuin-activating compounds in Alzheimer's disease. Drug News Perspect. 20:233-39
157. Selkoe DJ. 2007. Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. Nutr. Rev. 65:S239-43
158. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, et al. 2007. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447:859-63
159. Outeiro TF, Marques O, Kazantsev A. 2008. Therapeutic role of sirtuins in neurodegenerative disease. Biochim. Biophys. Acta 1782:363-69
160. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, et al. 2008. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. USA 105:15564-69
161. Winklhofer KF. 2007. The parkin protein as a therapeutic target in Parkinson's disease. Expert Opin. Ther. Targets 11:1543-52
162. Lim KL, Tan JM. 2007. Role of the ubiquitin proteasome system in Parkinson's disease. BMC Biochem. 8(Suppl. 1):S13
163. Valdmanis PN, Rouleau GA. 2008. Genetics of familial amyotrophic lateral sclerosis. Neurology 70:144-52
164. Gruzman A,Wood WL, Alpert E, Prasad MD,Miller RG, et al. 2007. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 104:12524-29
165. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, et al. 2008. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 11:251-53
166. Winyard PG, Moody CJ, Jacob C. 2005. Oxidative activation of antioxidant defence. Trends Biochem. Sci. 30:453-61
167. SangsterTA, Salathia N, Undurraga S, Milo R, Schellenberg K, et al. 2008. HSP90 affects the expression of genetic variation and developmental stability in quantitative traits. Proc. Natl. Acad. Sci. USA 105:2963-68
168. Rutherford S, Hirate Y, Swalla BJ. 2007. The Hsp90 capacitor, developmental remodeling, and evolution: the robustness of gene networks and the curious evolvability of metamorphosis. Crit. Rev. Biochem. Mol. Biol. 42:355-72
169. Cowen LE, Lindquist S. 2005. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309:2185-89
170. Hopkins AL. 2008. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4:682-90
171. Gurkan C, Lapp H, Alory C, Su AI, Hogenesch JB, Balch WE. 2005. Large-scale profiling of Rab GTPase trafficking networks: the membrane. Mol. Biol. Cell 16:3847-64